PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media287922ArticlesСтатьиResearch ArticleNovye vozmozhnosti profilaktiki toshnoty i rvoty pri provedenii khimioterapiiНовые возможности профилактики тошноты и рвоты при проведении химиотерапииAbramovM. EАбрамовМ. Е

к.м.н., с.н.с.

mikhailabramov@newmail.ruLodyginaK. SЛодыгинаК. С

ординатор кафедры онкологии и лучевой терапии

ФГБНУ «Онкологический научный центр им. Н.Н. Блохина»ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России20042015228NO8 (2015)№8 (2015)101526022023Copyright ©; 2015, Bionika MediaCopyright ©; 2015, ООО «Бионика Медиа»2015Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/287922

The first representative of a new class of antiemetics - neurokinin-1 receptor antagonists (NK1) - is a selective NKIreceptor blocker -aprepitant (Emend®) and its intravenous form - Emend®IV. This formulation is more convenient to use, since it is given as a single dose intravenously before chemotherapy, has equal efficacy to aprepitant and, in contrast, does not require additional administration or an injection on subsequent days. Fosaprepitant was introduced in all clinical guidelines for the prevention of nausea and vomiting, in combination with 5-HT3 receptor antagonist and dexamethasone during highly- and, in some cases, moderately emetogenic chemotherapy. The drug has a minimum range of side effects.

Первым представителем нового класса антиэметиков - антагонистов нейрокининовых рецепторов-1 (NK1), является селективный блокатор рецепторов NK1 апрепитант(Эменд®) и его внутривенная форма Эменд® В/В. Этот препарат более удобен в использовании, т.к. вводится однократно внутривенно перед проведением химиотерапии, имеет равную эффективность с апрепитантом и в отличие от него не требует дополнительного приема или введения в последующие дни. Фосапрепитант вошел во все клинические рекомендации для профилактики тошноты и рвоты в комбинации с антагонистом рецептора 5-НТ 3 и дексаметазоном при проведении высоко- и в некоторых случаях умеренноэметогенной химиотерапии. Препарат обладает минимальным спектром побочных действий.

fosaprepitantaprepitantNK-I receptor antagonistschemotherapynauseavomitingантиэметикиантагонисты нейрокининовых рецепторовфосапрепитантапрепитантхимиотерапиятошнотарвотаHesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy induced nausea and vomiting. Support Care Cancer. 2001;9:350-54.Hesketh PJ., Grunberg S. M., Gralla R.J., Warr D. G., Roila F., de Wit R., Chawla S.P., Car ides A.D., lanus J, Elmer M.E., Evans J.K., Beck K., Reines S., Horgan K.J.; Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J. Clin. Oncol. 2003; 21:4112-19.Poli-Bigelli S., Rodrigues-Pereira J., Carides A.D., Julie Ma G., Eldridge K., Hipple A., Evans J.K., Horgan K.J., Lawson F.; Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-98.de Witt R., Herrstedt J., Rapoport B., Carides A.D., Guoguang-Ma J., Elmer M., Schmidt C., Evans J.K., Horgan K.J. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase Ill trials. Eur. J. Cancer. 2004;40:403-10.Hargreaves R., Ferreira J.C., Hughes D., Brands J., Hale J., Mattson B., Mills S. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann. NY. Acad. Sci. 2011; 1222:40-8.Langford P., Chrisp P. Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid. 2010;5:77-90.Lasseter K.C., Gambale J., Jin B., Bergman A., Constanzer M., Dru J., Han T.H., Majumdar A., Evans J.K., Murphy M.G. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J. Clin. Pharmacol. 2007; 47:834-40.FDA approval letter of emend, NDA 21-549. www.accessdata.fda.gov/drugsatfda_docs/ appletter/2003/21549ltr.pdf.Feyer P. Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol. 2011;22(1):30-38.Ivemend: EPAR - Public assessment report. www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_ Public_assessment_report/human/000743/WC500037156.pdf.FDA approval letter of fosaprepitant, NDA 022023/S-004. www.accessdata.fda.gov/drug-satfda_docs/appletter/2010/022023s004ltr.pdf.Ivemend 150 mg: EPAR - Procedural steps taken and scientific information after authorisation. www. ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Procedural_steps_taken_and_scientific_ information_after_authorisation/human/000743/ WC500037157.pdf.Van Laere K., De Hoon J., Bormans G., Koole M., Derdelinckx I., De Lepeleire I., Declercq R., Sanabria Bohorquez S.M., Hamill T., Mozley P.D., Tatosian D., Xie W., Liu Y., Liu F., Zappacosta P., Mahon C., Butterfield K.L., Rosen L. B., Murphy M. G., Hargreaves R.J., Wagner J.A., Shadle C.R. Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging. Clin. Pharmacol. Ther. 2012;92(2): 243-50.EMEND label. www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm?fuseaction=Search. Label_ApprovalHistory.Cheer S.M., Prakash A., Faulds D., Lamb H.M. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003; 63(1):101-33.Warr D.G., Hesketh P.J., Gralla R.J., Muss H.B., Herrstedt J., Eisenberg P.D., Raftopoulos H., Grunberg S.M., Gabriel M., Rodgers A., Bohidar N., Klinger G., Hustad C.M., Horgan K.J., Skobieranda F. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. 2005;23:2822-30.Fujii T., Nishimura N. et al. Differential Impact of Fosaprepitant on Infusion Site Adverse Events Between Cisplatin- and Anthracycline-based Chemotherapy Regimen. Anticancer Res. 2015;35:379-84.Kakuta N., Tsutsumi Y.M., Horikawa Y.T., et al. Neurokinin-1 receptor antagonism, aprepitant, effectively diminishes post-operative nausea and vomiting while increasing analgesic tolerance in laparoscopic gynecological procedures. J. Med. Investigation. 2011;58(3-4):246-51.Grunberg S., Chua D., Anish Maru. Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol - EASE, JCO. 2011 ;29( 1 ).Hesketh P.J., Kris M.G., Grunberg S.M. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin. Oncol. 1997;15:103-09.Shillingburg A., Biondo L. Aprepitant and Fosaprepitant Use in Children and Adolescents at an Academic Medical Center. J. Pediatr. Pharmacol. Ther. 2014;19(2):127-31.Saito H., Yoshizawa H., Yoshimori K., Katakami N., Katsumata N., Kawahara M., Eguchi K. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann. Oncol. 2013;24(4):1067-73.Ihbe-Heffinger A., Ehlken B., Bernard R., Berger K., Peschel C., Eichler H.G., Deuson R., Thödtmann J., Lordick F. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann. Oncol. 2004;15(3):526-36.Vanscoy G.J., Fortner F., Smith R., Weber R., Rihn T.L. Preventing chemotherapy induced nausea and vomiting: the economic implications of choosing antiemetics. Comm. Oncol. 2006;2:127-32.Bergstrom M., Hargreaves R.J., Burns H.D., Goldberg M.R., Sciberras D., Reines S.A., Petty K.J., Ogren M., Antoni G., Lеngstrum B., Eskola O., Scheinin M., Solin O., Majumdar A.K., Constanzer M.L., Battisti W.P., Bradstreet T.E., Gargano C., Hietala J. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry. 2004;55: 1007-12.Roila F., Herrstedt J., Aapro M., Gralla R.J., Einhorn L.H., Ballatori E., Bria E., Clark-Snow R.A., Espersen B.T., Feyer P., Grunberg S.M., Hesketh P.J., Jordan K., Kris M.G., Maranzano E., Molassiotis A., Morrow G., Olver I., Rapoport B.L., Rittenberg C., Saito M., Tonato M., Warr D. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann. Oncol. 2010;21(Suppl. 5):v232-43.Feyer P., Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann. Oncol. 2011;22 (1):30-38.